Pharma & Biotech

A notable surge in institutional investment activity and revised analyst outlooks are driving significant momentum for Amicus Therapeutics. Recent regulatory...

Medical technology firm Haemonetics finds itself at the center of a curious market contradiction. The company recently posted quarterly results...

A superficial glance at Oramed's latest quarterly report suggests a company in good health, having posted a net profit. However,...

BridgeBio Pharma has captured significant attention following compelling long-term data presented at the European Society of Cardiology congress. The biopharmaceutical...

Ocugen has achieved a critical regulatory milestone after European Medicines Agency (EMA) officials endorsed the company's development strategy for its...

Despite reporting progress in its pivotal Phase 3 trial for a hepatitis C combination therapy, Atea Pharmaceuticals Inc. witnessed its...

Autolus Therapeutics presents investors with a compelling puzzle. The clinical-stage biopharmaceutical company boasts a recently approved cancer therapy and impressive...

PepGen Inc. finds itself navigating a perfect storm of declining investor confidence, legal challenges, and a strategic pipeline overhaul. The...

Enzo Biochem Inc. has concluded its tenure as a publicly traded company following its full acquisition by the private equity...

The investment narrative surrounding transplant diagnostics firm CareDx is one of stark contrasts. The company’s latest quarterly results revealed significant...